INS and diabetes mellitus: The only ongoing therapy was that for DM, based on continuous subcutaneous rapid-acting insulin analog infusion with a hybrid closed loop system (Tandem Control-IQ and Dexcom G6), and off-label once-daily 1.8 mg liraglutide subcutaneous injection.